Antiviral agent

Abstract

An objective of the present disclosure is to provide a novel antiviral agent capable of imparting an antiviral effect on a space, an article, a human body, or the like. An antiviral agent according to the present disclosure is characterized by containing at least one compound selected from the group consisting of 1-octene-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid.

Description

antiviral agents

[0001] The present disclosure relates to an antiviral agent that can impart antiviral effects to spaces, objects, the human body, etc.

[0002] Viruses cause deterioration of the living environment, decay, infection, etc., so antiviral agents are used to combat them. Most conventional antiviral agents are non-volatile, but volatile ones are also known.

[0003] Non-volatile antiviral agents must be used by being directly attached to or contained in a target object, whereas volatile antiviral agents can be simply placed in the target space or a space where the target object is present and allowed to volatilize, allowing the antiviral effect to permeate every corner of the target space or target object, making them superior in terms of ease of use.

[0004] As antiviral agents, Patent Document 1 reports 2-phenylethyl formate, benzyl acetate, methoxycitronellal, cinnamyl alcohol, hydratropic alcohol, dimethylbenzyl carbinol, trans-2-hexen-1-ol, trans-3-hexenol, cis-3-hexenol, and 3-phenylpropionaldehyde, while Patent Document 2 reports α-pinene, β-pinene, d-limonene, and sandalwood oil.

[0005] In recent years, awareness of infection prevention and hygiene has increased, and there is a demand for further development of antiviral agents.

[0006] JP 2023-63142 JP 8-26980

[0007] An object of the present disclosure is to provide a new antiviral agent that can impart antiviral activity to spaces, objects, the human body, etc.

[0008] The present inventors conducted extensive research to solve the above problems and found that 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid have excellent antiviral activity and can be used as antiviral agents. The present inventors also found that these compounds are volatile and can impart antiviral activity to a target substance even in a volatilized state. The present invention was completed based on these findings and through further research.

[0009] That is, the present disclosure provides the following aspects of the invention. Item 1. An antiviral agent comprising at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid. Item 2. An antiviral composition for use in air, comprising the antiviral agent according to Item 1 and a solvent. Item 3. An antiviral composition for use in an article, comprising the antiviral agent according to Item 1 and a solvent. Item 4. The antiviral composition for use in an article according to Item 3, wherein the article is a textile product. Item 5. The antiviral composition for use in an article according to Item 3, wherein the article has a hard surface. Item 6. Use of at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid for antiviral purposes in air or an article. Item 7. Item 7. Use of a composition comprising at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid, and a solvent, for antiviral purposes in a space or an article. Item 8. Use of a composition comprising at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid, and a solvent, as an antiviral composition for use in a space. Item 9. Use of a composition comprising at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid, and a solvent, as an antiviral composition for use in an article. Item 10. The use according to Item 9, wherein the article is a textile product. Item 11. The use according to Item 9, wherein the article has a hard surface. Item 12. Item 12. An antiviral method for treating an object for which antiviral properties are desired with at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid. Item 13. An antiviral method for treating an object for which antiviral properties are desired with a composition comprising at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid, and a solvent. Item 14. The method according to Item 12 or 13, wherein the object for which antiviral properties are desired is a space, and the space is treated with the compound or composition.Item 15. The method of Item 12 or 13, wherein the object for which antiviral properties are desired is an article, and the article is treated with the compound or composition. Item 16. The method of Item 15, wherein the article is a textile product. Item 17. The method of Item 15, wherein the article has a hard surface. Item 18. Use of at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid for the production of an antiviral composition.

[0010] According to the present disclosure, a novel antiviral agent is provided. Moreover, by volatilizing the antiviral agent in a space, the antiviral agent of the present disclosure can impart antiviral activity not only to the space but also to objects present in the space and components that partition the space, thereby making it possible to create a hygienic living environment in a simple manner and reduce the risk of contracting an infectious disease.

[0011] 1. Definitions In the present disclosure, the notation "X to Y" regarding a numerical range indicates a numerical range of not less than X and not more than Y.

[0012] In the present disclosure, volatile means volatilizing at room temperature and normal pressure (20°C, 1 atmosphere).

[0013] In this disclosure, antiviral refers to reducing the activity of a virus, resulting in a decrease in the virus or a decrease in the infectivity of the virus. In this disclosure, antiviral agent refers to a substance used for antiviral purposes.

[0014] In the present disclosure, an antiviral composition for space refers to a composition used by treating a space with an antiviral agent for the purpose of making the space antiviral.

[0015] In the present disclosure, an antiviral composition for an article refers to a composition used by treating an article with an antiviral agent for the purpose of making the article antiviral.

[0016] In this disclosure, topical antiviral compositions refer to compositions that are applied to the skin for antiviral purposes.

[0017] In the present disclosure, an antiviral method refers to a method of imparting an antiviral effect to a subject in need of antiviral treatment.

[0018] In the present disclosure, a hard surface refers to the surface of a hard member such as resin, ceramic, or glass.

[0019] 2. Antiviral Agent The antiviral agent of the present disclosure is characterized by containing, as an active ingredient, at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid. The antiviral agent of the present disclosure is described in detail below.

[0020] [Active ingredient] The antiviral agent of the present disclosure contains, as an active ingredient, at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid. All of the compounds are volatile compounds.

[0021] In the antiviral agent of the present disclosure, one active ingredient may be selected from 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid and used alone, or two or more active ingredients may be used in combination.

[0022] Among the above compounds, methacrylic acid, propionic acid, and isobutyric acid are preferred from the viewpoint of exhibiting a more excellent antiviral effect on synthetic resins such as polyethylene terephthalate and polyurethane.

[0023] [Viruses to which it can be applied] The antiviral agent of the present disclosure can inhibit the growth of a wide variety of viruses.

[0024] The type of virus to which the antiviral agent of the present disclosure is applied is not particularly limited and may be either an enveloped virus or a non-enveloped virus. Specifically, enveloped viruses to which the antiviral agent of the present disclosure is applied include influenza virus, coronaviruses (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1), novel coronavirus (SARS-CoV-2), herpes virus, respiratory syncytial virus, etc. Non-enveloped viruses to which the antiviral agent of the present disclosure is applied include feline calicivirus, norovirus, rotavirus, poliovirus, adenovirus, etc. Among these viruses, influenza virus, feline calicivirus, and norovirus are preferred examples of viruses to which the antiviral agent of the present disclosure is applied.

[0025] [Target of application, method of use, etc.] The antiviral agent of the present disclosure is used to impart an antiviral effect to a target for which antiviral action is required by treating the target. Targets for which antiviral action is required include not only spaces or articles, etc. in which viruses are present or attached, but also spaces or articles, etc. in which inhibition of virus attachment is required even when viruses are not present or attached.

[0026] By treating a space with the antiviral agent of the present disclosure, an antiviral effect can be imparted not only to the space but also to items present in the space. Examples of items present in the space that can be imparted with an antiviral effect include trash cans, sofas, chairs, desks, electrical appliances, sinks, toilets, bathtubs, washbasins, curtains, carpets, bedding, clothing, shoes, leather products, storage furniture, wallpaper, doors, floors, windows, and ceilings.

[0027] To treat a space with the antiviral agent of the present disclosure, the antiviral agent of the present disclosure may be volatilized or sprayed in the space. When the antiviral agent of the present disclosure is used for antiviral purposes in a space, the antiviral agent of the present disclosure may be mixed with a volatilizable solvent to provide an antiviral composition for use in a space.

[0028] The content of the antiviral agent of the present disclosure in an antiviral composition for spatial use may be set appropriately depending on the type, size, and the like of the space to which it is to be applied; for example, the amount of the compound is 0.1 to 99.9% by weight, preferably 1 to 99.9% by weight, and more preferably 1 to 80% by weight.

[0029] The solvent used in the antiviral composition for air space may be any solvent that can solubilize or disperse the antiviral agent of the present disclosure and that is volatilizable at room temperature, and examples thereof include water, paraffinic hydrocarbons (plasma fluid isoparaffin, plasma fluid normal paraffin), 3-methoxy-3-methyl-1-butanol, propylene glycol monomethyl ether, etc. These solvents may be used alone or in combination of two or more. In the antiviral composition for air space, the content of the solvent may be any solvent as long as it accounts for the remainder other than the antiviral agent of the present disclosure and any additives added as needed.

[0030] Furthermore, the antiviral composition for spatial use may contain other additives in addition to the antiviral agent of the present disclosure. Examples of other additives that can be incorporated into the antiviral composition for spatial use include surfactants, antioxidants, pH adjusters, fragrances, deodorizers, disinfectants, UV absorbers, insecticidal components, insect repellent components, repellent components, gelling agents, etc.

[0031] The form of the antiviral composition for spatial use is not particularly limited as long as it allows the antiviral agent of the present disclosure to be vaporized or sprayed; for example, if the composition is to be left to volatilize by standing, it may be in a liquid or gel form, or if the composition is to be sprayed, it may be in a liquid form.

[0032] To volatilize the antiviral composition for air in a space, the antiviral composition for air can be left stationary in the space in a volatilizable state in the same manner as conventional stationary air fresheners. To spray the antiviral composition for air in a space, a spray container, an aerosol container, an ultrasonic diffuser, an electric diffuser, or the like can be used.

[0033] The space to which the antiviral composition for spatial use can be applied may be any space that is separated from the outdoors, and examples thereof include box spaces such as trash cans and shoe cabinets; indoor spaces such as living rooms, toilets, bathrooms, washrooms, entrance halls, and closets; interior spaces of automobiles, buses, trucks, and the like; and spaces within facilities such as restaurants, factories, offices, and conference rooms.

[0034] Antiviral Use of Articles By treating an article with the antiviral agent of the present disclosure, an antiviral effect can be imparted to the article.

[0035] To treat an article with the antiviral agent of the present disclosure, the antiviral agent of the present disclosure may be applied or sprayed onto the article. When the antiviral agent of the present disclosure is used for antiviral purposes on an article, the antiviral agent of the present disclosure may be mixed with a solvent to provide an antiviral composition for the article.

[0036] The content of the antiviral agent of the present disclosure in the antiviral composition for articles may be set appropriately depending on the space to which it is to be applied, the type of article, and the like; for example, the amount of the compound is 0.1 to 99.9 wt %, preferably 1 to 99.9 wt %, and more preferably 1 to 80 wt %.

[0037] The solvent used in the antiviral composition for articles may be any solvent that can solubilize or disperse the antiviral agent of the present disclosure, and examples thereof include water, ethanol, propanol, etc. These solvents may be used alone or in combination of two or more. In the antiviral composition for articles, the content of the solvent may be any content that accounts for the remainder other than the antiviral agent of the present disclosure and any additives added as needed.

[0038] Furthermore, the antiviral composition for an article may contain other additives in addition to the antiviral agent of the present disclosure. Examples of other additives that can be incorporated into the volatile antiviral composition include surfactants, antioxidants, pH adjusters, fragrances, deodorizers, disinfectants, UV absorbers, insecticidal components, insect repellent components, and repellent components.

[0039] To facilitate application or spraying of the antiviral composition for an article to be used, the composition may be provided in the form of a wipe sheet obtained by impregnating a fabric such as a nonwoven fabric with the composition, or in the form of a spray or aerosol.

[0040] Examples of articles to which the antiviral composition for articles can be applied include textile products such as fabric sofas, bedding, clothing, curtains, masks, diapers, wet towels, and carpets; hard surfaces such as toilets, bathtubs, washbasins, sinks, tiles, and glass; architectural structures such as wallpaper, doors, handrails, floors, windows, and ceilings; trash cans, chairs, desks, electrical appliances, storage furniture, shoe cabinets, shoes, and leather products.

[0041] Another suitable example of an article to which the antiviral agent of the present disclosure is applied is a textile product.

[0042] Further, still another suitable example of an article to which the antiviral agent of the present disclosure is applied is a hard surface, particularly a hard surface made of plastic. In a suitable embodiment when treating a hard surface with the antiviral agent of the present disclosure, at least one compound selected from the group consisting of methacrylic acid, propionic acid, and isobutyric acid is used as the antiviral agent of the present disclosure.

[0043] - Antiviral use for the body When applied to the skin, the antiviral agent of the present disclosure can impart antiviral effects to the skin and keep the skin in a hygienic state.

[0044] When the antiviral agent of the present disclosure is applied to the skin, it may be provided as an antiviral external composition containing the antiviral agent of the present disclosure.

[0045] The content of the antiviral agent of the present disclosure in the antiviral composition for topical use may be set appropriately depending on the formulation form of the composition for topical use, etc., and examples of the amount of the compound include 0.1 to 50 wt %, preferably 0.1 to 30 wt %, and more preferably 0.1 to 10 wt %.

[0046] The antiviral topical composition may be formulated by blending additives and bases with the antiviral agent of the present disclosure. The antiviral topical composition may be in any formulation, such as a topical skin drug, cosmetic, or skin cleanser, as long as it is applied to the skin. Specific examples of the formulation of the antiviral topical composition include topical skin drugs such as creams, lotions, gels, emulsions, liquids, poultices, patches, liniments, aerosols, aqueous ointments, packs, hand gels, and hand sanitizers; cosmetics such as aqueous ointments, creams, emulsions, lotions, packs, and gels; and skin cleansers such as body shampoos, hair shampoos, rinses, and wet wipes.

[0047] Use for the purpose of improving shelf life or durability When incorporated into products requiring antiviral properties, the antiviral agent of the present disclosure can also function as a preservative and improve the shelf life or durability of the product.

[0048] The types of products that require antiviral properties are not particularly limited, but examples include foods, pharmaceuticals, cosmetics, textile products, resin products, and paper products.

[0049] The content of the antiviral agent of the present disclosure in the product may be set as appropriate depending on the type of product and the like, and examples of the amount of the compound include 0.1 to 50% by weight, preferably 0.1 to 30% by weight, and more preferably 0.1 to 10% by weight.

[0050] When the product is a food, pharmaceutical, or cosmetic, the antiviral agent of the present disclosure may be blended as an additive. When the product is a textile, resin, or paper product, the antiviral agent of the present disclosure may be kneaded into the materials used in the production of these products.

[0051] The present disclosure will be explained in more detail below by showing examples, but the present disclosure is not limited to these examples.

[0052] Test Example 1: Evaluation of antiviral activity on fiber surfaces 1. Test materials and test method In this test, a fiber piece was left standing in an environment where volatile substances had been evaporated, and then the fiber piece was left standing in contact with a test virus to evaluate the antiviral activity of the fiber piece. The specific test materials and test method are as follows.

[0053] (1) Test Viruses Influenza A virus (H1N1); strain: ATCC VR-1469, host cells: MDCK (NBL-2) cells) and feline calicivirus (strain: ATCC VR-782, host cells: CRFK cells) were prepared as test viruses.

[0054] (2) Preparation of test virus solution The prepared host cells were inoculated with the virus solution diluted with EMEM(-) and cultured overnight at 37°C in the presence of 5% CO2. After centrifugation, the supernatant was collected to prepare 1.0 x 10 7 ~1.0×10 8 A virus suspension of pfu / mL was prepared, and then the resulting virus suspension was diluted 10-fold with sterile purified water to prepare a test virus solution.

[0055] (3) Preparation of Test Samples Undiluted solutions (100%) of the volatile substances shown in Table 1 and diluted solutions obtained by diluting them with isoparaffin to the concentrations shown in Table 1 were used as test samples.

[0056] (4) Preparation of Test Sample-Treated and Untreated Fibers. A 0.4 g piece of cut cotton cloth (2 cm × 2 cm square) and a glass dish B (2.6 cm diameter, 1.2 cm height) were placed side by side on the inner bottom of a glass Petri dish A (8.5 cm diameter, 3.0 cm height). 0.5 mL of the test sample was added to the inside of glass Petri dish B, and the glass dish A was covered to prevent contact between the test sample and the cotton cloth in an enclosed space. In this state, the test sample was left to stand at room temperature for 30 minutes when a 10% diluted solution was used, and for 3 hours when a 30% diluted solution or the undiluted solution (100%) was used, to obtain test sample-treated fibers. The test sample-treated fibers were prepared immediately before the antiviral test described below. Additionally, 0.4 g of untreated cotton cloth (2 cm × 2 cm square) was prepared as an untreated fiber.

[0057] (5) Antiviral Test: Test specimen-treated or untreated fibers were placed in a vial, and 200 μL of the test virus solution was inoculated evenly over the entire surface of the test specimen-treated or untreated fibers. The vial was then capped and allowed to stand at 25°C for 18 hours. Next, 20 mL of SCDLP liquid medium was added to the vial, and the mixture was thoroughly stirred to disperse the virus in the SCDLP liquid medium, yielding a virus dispersion. Then, 0.1 mL of the virus dispersion was added to 0.9 mL of EMEM(-), and the number of plaques was counted by the plaque assay. The antiviral activity value was calculated according to the following formula:

[0058] The antiviral effect was evaluated based on the antiviral activity value according to the following criteria: <Criteria for evaluating antiviral effect> A: Antiviral activity value of 3.0 or more (high antiviral effect) B: Antiviral activity value of 2.0 or more but less than 3.0 (antiviral effect) C: Antiviral activity value of less than 2.0 (no antiviral effect)

[0059] 2. Test Results The results are shown in Table 1. The fiber pieces placed in a space where 1-octen-3-ol, propionic acid, methacrylic acid, isobutyric acid, or pentanal had evaporated exhibited excellent antiviral activity against influenza virus or feline calicivirus (Examples 1 to 5). However, the fiber pieces placed in a space where hexanol or octanol had evaporated did not have antiviral activity against influenza virus or feline calicivirus (Comparative Examples 1 and 2).

[0060]

[0061] Test Example 2: Evaluation of antiviral activity on hard surfaces 1. Test materials and test method In this test, a polyurethane plate was placed in an environment where volatile substances had evaporated, and then the plate was placed in contact with a test virus to evaluate the antiviral activity of the plate. The test materials and test method were the same as those in Test Example 1 above, except that a polyurethane plate (4.8 cm x 4.8 cm square) was used instead of the fiber piece and the amount of test virus solution placed in the vial was changed to 400 μL.

[0062] 2. Test Results The results are shown in Table 2. The polyurethane plates placed in a space where propionic acid, methacrylic acid, or isobutyric acid had evaporated exhibited excellent antiviral activity against influenza virus or feline calicivirus (Examples 2 to 4). However, the polyurethane plates placed in a space where hexanol or octanol had evaporated did not have antiviral activity against influenza virus or feline calicivirus (Comparative Examples 1 and 2).

[0063]

Claims

1. An antiviral agent comprising at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid.

2. An antiviral method, which comprises treating a target for which antiviral properties are desired with at least one compound selected from the group consisting of 1-octen-3-ol, pentanal, methacrylic acid, propionic acid, and isobutyric acid.

Images